Loading
Life sciences · Journal article
Nature Genetics · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Estrogen receptor (ER)-positive breast cancer treatment is based primarily on endocrine therapy. To dissect mechanisms of sensitivity to aromatase inhibitors in ER-positive breast cancer, we profiled tumor biopsies from 25 patients during neoadjuvant therapy using single-cell RNA sequencing, immune receptor sequencing and enhancer activity mapping. Malignant cells with high ER signaling and elevated activity of enhancers with ER binding sites were sensitive to treatment. Resistance was associated with androgen receptor signaling, dedifferentiation and epithelial–mesenchymal transition. Poor responders preferentially used the androgen receptor cis-regulome under treatment pressure. The baseline tumor microenvironment was associated with tumor downstaging. Poor responders exhibited a ‘hot’, yet ineffective immune landscape enriched for naive lymphoid and undifferentiated myeloid cells. Good responders showed an active immune microenvironment with sustained clonal expansion of T cells. Our longitudinal single-cell analyses elucidate the genetic, cellular and epigenetic mechanisms driving sensitivity and resistance to neoadjuvant aromatase inhibition in ER-positive breast cancer. This longitudinal single-cell study of estrogen receptor (ER)-positive breast cancer suggests that strong estrogen signaling, ER-linked enhancers and active T cell responses could predict sensitivity to aromatase inhibitors, whereas resistance involves androgen signaling though hormone-sensing enhancer activity.